The Transplant Threshold

This flow traces how Kidney transplantation becomes both the preferred renal replacement therapy and a new arena of HCV-related danger.

increasingBearing stren­gth in each eventdecreasing

Transplant Advantage

Transplant Advantage Leaving dialysis Despite HCV-related hazards, Kidney transplantation offers better survival than remaining on dialysis for suitable patients. The decision therefore balances infection against the mortality of prolonged End-stage renal disease. Conditional hope The benefit depends on excluding advanced liver injury and evaluating extrahepatic complications. Transplantation is not a cure for HCV, but it can change the odds of survival.

Pretransplant Staging

Pretransplant Staging Hidden fibrosis Many candidates have substantial fibrosis or cirrhosis despite mild symptoms and deceptively low aminotransferase levels. Liver biopsy remains the central method for determining whether kidney-alone transplantation is safe. A fork in destiny Compensated disease may permit kidney transplantation, while decompensated cirrhosis redirects the candidate toward Liver-kidney combined transplantation. The biopsy turns an invisible risk into a formal allocation decision.

Posttransplant Vulnerability

Posttransplant Vulnerability Immunosuppression changes the terrain Viral replication may rise after transplantation, while diabetes, infection, glomerulonephritis, rejection, and progressive liver disease threaten both graft and recipient. The new kidney introduces survival but also new biological pressure. Continued preference Long-term outcomes remain inferior to those of uninfected recipients, yet transplantation still generally outperforms dialysis. The result is a qualified victory requiring surveillance rather than a clean resolution.

before transplantation

during candidate evaluation

after Kidney transplantation